SCHEMBL7963288

SCHEMBL7963288

COc1c(C(N)=O)csc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
NPC1 O15118 4/20 0.45
RAB9A P51151 3/20 0.45
POLB P06746 3/20 0.45
FFAR2 O15552 1/20 0.38
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 4/20 0.36
HTT P42858 3/20 0.36
MAPK10 P53779 2/20 0.36
IKBKB O14920 1/20 0.35
GAA P10253 3/20 0.35
NNMT P40261 2/20 0.35
CASP1 P29466 1/20 0.35
HTR1A P08908 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TSHR P16473 2/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
MAPK1 P28482 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1328328 0.83 MEN1 (0.49) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL3060301 0.83 MEN1 (0.49) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL4004768 0.83 MEN1 (0.49) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL7963283 0.81 MEN1 (0.48) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL11472415 0.81 LMNA (0.45) MEN1KMT2AKDM4EALDH1A1HTT
SCHEMBL8630022 0.75 GSK3B (0.39) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL6361656 0.73 KMT2A (0.50) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL11039311 0.69 NNMT (0.52) MEN1KMT2AKDM4EALDH1A1HTT
SCHEMBL10407305 0.68 ALDH1A1 (0.52) KMT2AKDM4EALDH1A1HTTGAA
SCHEMBL13990270 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192646-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2023-06-22 US claimed
EP-4081299-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2022-11-02 EP claimed
CN-114867525-A Dihydrocyclopentaisoquinoline derivatives UCB生物制药有限责任公司 2022-08-05 CN claimed
WO-2021130255-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2021-07-01 WO claimed
US-20230192646-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2023-06-22 US disclosed
EP-4081299-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2022-11-02 EP disclosed
CN-114867525-A Dihydrocyclopentaisoquinoline derivatives UCB生物制药有限责任公司 2022-08-05 CN disclosed
WO-2021130255-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2021-07-01 WO disclosed
WO-2001007409-A1 CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS ASTRAZENECA UK LIMITED (GB) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192646-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES FCER2, FCGR2A, FCGR1A MEN1 4763/4885KMT2A 3223/4885NPC1 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.